Table 1.
Second generation glyco-engineered anti-CD20 antibodies currently in clinical development.
| GA101 | LFB-R603 | BLX-301 | |
|---|---|---|---|
| Company | Roche [Glycart] | LFB Biotechnologies [GTC Biotherapeutics] | Biolex |
| Format | Humanized | Chimæric | Humanized |
| Type of anti-CD20 | Type II | Type I | NA |
| Glyco-engineering | Low fucose | Low fucose | No fucose / G0 |
| CDC* | ↘ | = | ↘ |
| ADCC** | ↗ | ↗ | ↗ |
| PCD° | ↗ | = | NA°° |
| Phase Development | Phase II | Phase I/II | Pre-clinical |
| Indication | NHL / CLL+ | CLL | NHL |
| Reference | [51] | [34] | NA |
* CDC: complement-dependent cytotoxicity, ** ADCC: antibody-dependent cell cytotoxicity; ° PCD: programmed cell death induction, °° NA: not available; + CLL: chronic lymphocytic leukemia.